PrescriptionDrugs.org

What to Expect When Starting Valsartan

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

Introduction

Valsartan (brand name Diovan) is an angiotensin II receptor blocker (ARB) prescribed for hypertension, heart failure, and post-myocardial infarction management [1]. It works by selectively blocking the angiotensin II type 1 (AT1) receptor, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II [2]. Unlike ACE inhibitors, ARBs do not affect bradykinin metabolism, which means the persistent dry cough common with ACE inhibitors is much less likely with valsartan — making it an excellent alternative for patients who could not tolerate ACE inhibitors.

Week-by-week timeline

Week 1-2First-dose hypotension is less common than with ACE inhibitors but can occur in volume-depleted patients. Rise slowly from sitting positions for the first few days.

Starting the Initial Dose

For hypertension, begin with 80 mg or 160 mg once daily; for heart failure, start at 40 mg twice daily [1]. Blood pressure reduction begins within 2 hours of the first dose, with peak effect at 4-6 hours. The full antihypertensive effect at any given dose develops over 2-4 weeks [2]. Most patients tolerate valsartan well from the start. Common side effects include dizziness (2-4%), headache (4%), and fatigue (2%) — these are generally milder than with many other antihypertensives. Unlike ACE inhibitors, dry cough occurs at the same rate as placebo [1].

Week 2-4Hyperkalemia (elevated potassium) is uncommon at standard doses but should be monitored, especially with concurrent potassium supplements, potassium-sparing diuretics, or in patients with kidney disease.

Dose Titration

Your doctor may increase the dose based on blood pressure response: up to 320 mg daily for hypertension, or titrate up to 160 mg twice daily for heart failure [1]. Blood pressure should be measured regularly during titration. Kidney function (serum creatinine) and potassium levels are typically checked within 1-2 weeks of starting or increasing the dose [2]. A small rise in creatinine (up to 30%) is generally expected and acceptable with any renin-angiotensin system blocker.

Week 4-8Most patients with hypertension require 2 or more medications to reach target blood pressure. Adding a second drug is common and expected.

Reaching Full Antihypertensive Effect

By 4 weeks at a stable dose, valsartan provides its full blood pressure-lowering effect [2]. Blood pressure should be at or approaching the target range (typically <130/80 mmHg for most adults). If blood pressure remains above target on valsartan alone, your doctor may add a second antihypertensive, commonly a thiazide diuretic or calcium channel blocker — fixed-dose combinations are available. Side effects are generally mild and stable at this stage.

Month 3-6Continue taking valsartan even when blood pressure readings are normal — the medication is what is keeping them normal. Do not stop abruptly.

Long-Term Stabilization

Valsartan provides sustained cardiovascular protection. The Val-HeFT trial demonstrated a 13% reduction in the combined endpoint of morbidity and mortality in heart failure patients [3]. For hypertension, consistent blood pressure control reduces long-term risk of stroke, heart attack, and kidney disease. Periodic monitoring includes blood pressure, serum potassium, creatinine, and assessment of medication adherence. Valsartan is generally very well tolerated long-term with minimal ongoing side effects.

When to call your doctor

Contact your healthcare provider if you experience:

  • Swelling of the face, lips, tongue, or throat — angioedema is less common with ARBs than ACE inhibitors but can still occur and requires immediate emergency care [1]
  • Significant dizziness, fainting, or persistent lightheadedness, which may indicate excessive blood pressure reduction [1]
  • Decreased urine output, significant swelling in ankles or legs, or rapid weight gain — may indicate worsening kidney function or fluid retention [1]
  • Signs of hyperkalemia: muscle weakness, slow or irregular heartbeat, tingling — especially if taking potassium supplements [2]
  • If you discover you are pregnant while taking valsartan — ARBs can cause serious fetal harm and must be discontinued immediately [1]

Tips for getting started

Take valsartan at the same time each day, with or without food [1]. Avoid potassium supplements and salt substitutes containing potassium unless directed by your doctor. Stay hydrated, especially in hot weather or during exercise, to prevent dehydration-related drops in blood pressure. NSAIDs (ibuprofen, naproxen) can reduce valsartan's effectiveness and increase kidney risk — use acetaminophen for pain when possible [2]. If you previously stopped an ACE inhibitor due to cough, valsartan is typically well tolerated as an alternative. Women of childbearing potential must use reliable contraception — ARBs are teratogenic [1].

Frequently asked questions

More about Valsartan

References

  1. [Regulatory] Diovan (valsartan) FDA Prescribing Information. Novartis. Revised 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021283s043lbl.pdf Accessed 2025-01-15.
  2. [Regulatory] Valsartan. StatPearls [Internet]. National Library of Medicine. Updated 2024. https://www.ncbi.nlm.nih.gov/books/NBK563269/ Accessed 2025-01-15.
  3. [Clinical] Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure (Val-HeFT). N Engl J Med. 2001;345(23):1667-1675. https://pubmed.ncbi.nlm.nih.gov/11759645/ Accessed 2025-01-15.

Written and fact-checked by PrescriptionDrugs.org Editorial Team

Last updated: